Corporate Headquarters
505 Lomas Santa Fe Drive
Suite 270
Solana Beach, CA 92075

(858)345-1494 Tel.

Investor Relations :: Overview

Stock price graph

Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. EVK-001 is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration.


Mar 4, 2015
Evoke Pharma Fourth Quarter 2014 Conference Call

Nov 13, 2014 at 4:30 PM ET
Evoke Pharma Third Quarter 2014 Conference Call

Sep 22, 2014 Interview with Evoke Pharma CBO Matt D'Onofrio

Presentations and Posters

Evoke Pharma Investor Presentation PDF 1.6 MB  
Evoke Pharma Presentation at the LD Micro Conference. December 4, 2014 PDF 1.8 MB  
Texas Tech University Health Sciences Center PDF 622.5 KB  

Recent Releases

Apr 14, 2015
Evoke Pharma Achieves Significant Manufacturing Milestone With Successful Completion of Commercial Scale Production of EVK-001

Apr 9, 2015
Evoke Pharma Granted European Union Formulation Patent for EVK-001

View all releases »